Skip to content

A randomized, open-label, blank-controlled, multicenter trial for Shuang-Huang-Lian oral solution in the treatment of novel coronavirus pneumonia (COVID-19)

A randomized, open-label, blank-controlled, multicenter trial for Shuang-Huang-Lian oral solution in the treatment of novel coronavirus pneumonia (COVID-19)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000033133
Enrollment
Unknown
Registered
2020-05-21
Start date
2020-02-12
Completion date
Unknown
Last updated
2020-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Sponsors

The First Affiliated Hospital of Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with confirmed new coronavirus-infected pneumonia; 2. Aged >=18 years old; 3. Voluntarily sign written informed consent.

Exclusion criteria

Exclusion criteria: 1. Severe pneumonia requires mechanical ventilationcritically severe cases; 2. Estimated Time of Death is less than 48 hours; 3. There is clear evidence of bacterial infection in respiratory tract infections caused by basic diseases such as primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory malformations, congenital heart disease,and abnormal lung development; 4. Chest CT confirmed that patients with basic pulmonary diseases such as severe pulmonary interstitial lesions and bronchiectasis; 5. In the opinion of the investigator, previous or present illnesses may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, liver and kidney disease, blood disease, neurological disease, and endocrine Disease; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc.; 6. Mental state unable to cooperate, suffering from mental illness, unable to control, unable to express clearly 7. An allergic condition, such as a history of allergies to two or more drugs or foods, or a known allergy to the ingredients of the drug; 8. Patients with a history of substance abuse or dependence; 9. Pregnant or lactating women; 10. Patients who participated in other clinical trials within the last 3 months; 11. The investigator believes that there are any factors that are not suitable for enrollment or affect the evaluation of the efficacy.

Design outcomes

Primary

MeasureTime frame
Time to disease recovery;

Secondary

MeasureTime frame
Time and rate of coronavirus become negative;Clearance rate and time of main symptoms (fever, fatigue, cough);Exacerbation (transfer to RICU) time;Routine blood test;Biochemical Indicators;Pathogen detection: respiratory and fecal viral loads;

Countries

China

Contacts

Public ContactChen Yongping

The First Affiliated Hospital of Wenzhou Medical University

13505777281@163.com+86 13505777281

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026